Pharmaceutical company · AMGN

Amgen
clinical trial
pipeline

Registry checked

Published

Maridebart Cafraglutide is linked to 16 distinct active studies, with 2 Phase 1, 2 Phase 2, 12 Phase 3. Tarlatamab is linked to 12 distinct active studies, with 4 Phase 1, 3 Phase 2, 5 Phase 3.

Phase 2 study NCT06593522 in MTAP-deleted NSCLC lists estimated primary completion on 31 October 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

101active trials
as lead sponsor
  • Phase 124
  • Phase 217
  • Phase 350
  • Phase 47
  • Phase not recorded3

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

2115 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Recruitment status
RecruitingActive, not recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
29 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-022110042
2026-10-030010011
2026-10-040000000
2026-10-052100033
2026-10-060100011
2026-10-071100021
2026-10-080000000
2026-10-090001011
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000221
2026-10-251000453
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-301000011
Type totals842162115 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Maridebart Cafraglutide

Canonical investigational asset

16
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 22
  • Phase 312
  • Phase 40
  • Phase not recorded0
Studied condition
Atherosclerotic Cardiovascular Disease · Diabetes Mellitus, Type 2 · Heart Failure With Mildly Reduced Ejection Fraction
Next primary completion
21 January 2027 · estimated
Open drug

Tarlatamab

Canonical investigational asset

12
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 14
  • Phase 23
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Extensive Stage Small Cell Lung Cancer · Extensive Stage Small-cell Lung Cancer · Extensive-Stage Small-Cell Lung Cancer
Next primary completion
05 July 2027 · estimated
Open drug

inebilizumab

uplizna

9
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 24
  • Phase 34
  • Phase 41
  • Phase not recorded0
Studied condition
Active Refractory Rheumatoid Arthritis · AIH · Autoimmune Hepatitis
Next primary completion
13 April 2027 · estimated
Open drug

Xaluritamig

Canonical investigational asset

8
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 16
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Ewing Sarcoma · High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer · High-risk Biochemical Recurrence
Next primary completion
Not reported
Open drug

Blinatumomab

BLINCYTO

5
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
B Cell Precursor Acute Lymphoblastic Leukemia · B Precursor Acute Lymphoblastic Leukemia · Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Next primary completion
Not reported
Open drug

Anvumetostat

Canonical investigational asset

4
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 12
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers · Advanced MTAP-null Solid Tumors · MTAP-deleted NSCLC
Next primary completion
31 October 2026 · estimated
Open drug

98 of 101 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 98 of 101 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Amgen trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Anvumetostat

NCT06593522

Phase 2 · Active, not recruiting

Trial source and qualifications

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 7 inspected observations were not displayed.

7 candidate observations · 0 shown · 0 recorded after primary completion · 7 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

7 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 26 Dec 2024 · actual
    Primary completion: 31 Oct 2026 · estimated
    Study completion: 30 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    MTAPESTRY 101
    Anvumetostat

    NCT05094336

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 7 inspected observations were not displayed.

    7 candidate observations · 0 shown · 0 recorded after primary completion · 7 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    7 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 01 Feb 2022 · actual
      Primary completion: 30 Nov 2026 · estimated
      Study completion: 30 Nov 2026 · estimated

      2021202220232024202520262027202820292030
      Eucalyptus
      ABP 234

      NCT06430866

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

      4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      4 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 12 Sept 2024 · actual
        Primary completion: 14 Dec 2026 · estimated
        Study completion: 14 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
        AMG 732

        NCT06401044

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

        8 candidate observations · 3 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        5 inspected observations omitted. At most three verified observations are shown, not full history.

        • pc date moved · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • enrollment change · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • status flip · Recorded 2026-08-11 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 30 May 2024 · actual
        Primary completion: 06 Jan 2027 · estimated
        Study completion: 24 Dec 2027 · estimated

        2021202220232024202520262027202820292030
        MARITIME-1
        Maridebart Cafraglutide

        NCT06858839

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 12 Mar 2025 · actual
          Primary completion: 21 Jan 2027 · estimated
          Study completion: 16 Apr 2027 · estimated

          2021202220232024202520262027202820292030
          MARITIME-2
          Maridebart Cafraglutide

          NCT06858878

          Phase 3 · Active, not recruiting

          Trial source and qualifications

          Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

          2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          2 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 17 Mar 2025 · actual
            Primary completion: 21 Jan 2027 · estimated
            Study completion: 16 Apr 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 50 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 9 actual primary completions, 0 untyped primary completions, 1 past estimates, 7 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            42

            active trials in Oncology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Oncology42 trials
            • Metabolic/Endocrine/Nutrition25 trials
            • Neurology7 trials
            • Immunology & Inflammation6 trials
            • Cardiovascular3 trials
            • Pain & Musculoskeletal3 trials
            • Respiratory2 trials
            • Haematology1 trials
            • Ophthalmology1 trials
            • Renal & Urology1 trials
            • Unmapped8 trials
            • Healthy volunteers2 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            A

            AstraZeneca

            Shared indexed programme context · 2 selected assets

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Canonical current-owner attribution covers 1,075 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Amgen. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            1,075 distinct registry candidates produced 1,075 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            985 scoped records have indexed enrichment and 90 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-10-31T23:17:46.828Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 6f4cb5d222aeefe79a1f76537974460033cb4bf6ad1232a2c8218effa9f76ed8.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 1,075 mapped lead-sponsored clinical studies across all statuses. 985 have indexed enrichment, 90 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.